Key points are not available for this paper at this time.
In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Swain et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69dd1ef03ffc04feac1334c1 — DOI: https://doi.org/10.1056/nejmoa1413513
Sandra M. Swain
José Baselga
Sung‐Bae Kim
New England Journal of Medicine
Memorial Sloan Kettering Cancer Center
Heidelberg University
University Hospital Heidelberg
Building similarity graph...
Analyzing shared references across papers
Loading...